Company profile: Avila Therapeutics
1.1 - Company Overview
Company description
- Provider of covalent drugs for viral infections, cancers, and autoimmune diseases, designing and developing targeted small-molecule therapies including AVL-181, a hepatitis C virus protease inhibitor; partnered with Sanofi-Aventis.
Products and services
- ORENCIA (abatacept): Pharmaceutical-grade therapy for rheumatoid arthritis and other autoimmune diseases, supplying targeted management for immune-mediated conditions
- ELIQUIS (apixaban): Pharmaceutical-grade medication that reduces the risk of stroke and blood clots in people with atrial fibrillation, delivering targeted preventive treatment
- OPDIVO (nivolumab): Pharmaceutical-grade immunotherapy delivering treatment for various types of cancer, offering immune-based care across oncology indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Avila Therapeutics
Scorpion Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage precision oncology therapeutics, developing small-molecule inhibitors targeting the H1047X-mutant PI3Kα in solid tumors (STX-H1047-PI3Kα) and exon 20 insertion mutations in EGFR driving non-small cell lung cancer (STX-EGFR-EXON20).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scorpion Therapeutics company profile →
Admune Therapeutics
HQ: United States
Website
- Description: Provider of development and delivery of cytokine therapy drugs for cancer as a clinical-stage biotech company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Admune Therapeutics company profile →
Cargo Therapeutics
HQ: United States
Website
- Description: Provider of CAR T-cell therapies and platforms to overcome cancer treatment resistance and address access barriers. Products include CRG-022 (Firi-cel), a CD22-targeted CAR T for large B-cell lymphoma refractory or relapsed after CD19 CAR T; CRG-023, a tri-specific CAR T targeting CD19/CD20/CD22 with CD2 co-stimulation; a CD2 platform for activation in CD58-lacking tumors; and the STASH platform for multi-gene CAR T engineering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cargo Therapeutics company profile →
ArriVent BioPharma
HQ: United States
Website
- Description: Provider of pharmaceutical product development to cure presently untreatable cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArriVent BioPharma company profile →
IOmet Pharma
HQ: United Kingdom
Website
- Description: Provider of novel small-molecule medicines for the treatment of cancer, discovered and developed in the UK with particular emphasis on cancer immunotherapy and cancer metabolism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IOmet Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Avila Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Avila Therapeutics
2.2 - Growth funds investing in similar companies to Avila Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Avila Therapeutics
4.2 - Public trading comparable groups for Avila Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →